OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary

Rhea-AI Summary

OraSure Technologies (NASDAQ: OSUR) announced the retirement of Jack E. Jerrett, Senior VP and General Counsel, after nearly 21 years. Effective December 31, 2021, he will be succeeded by Agnieszka M. Gallagher, previously Chief Ethics and Compliance Officer at Alnylam Pharmaceuticals. Gallagher brings over 20 years of legal and compliance experience, including roles at major companies like ViiV Healthcare and GSK Vaccines. OraSure aims to maintain its leadership in diagnostic testing and sample collection technologies with this transition.

Positive

• Agnieszka M. Gallagher brings over two decades of executive leadership experience.
• Gallagher's previous roles in large biopharmaceutical companies may enhance OraSure's strategic direction.

Negative

• The retirement of a long-serving executive may create continuity challenges within the company.
• Potential experience gaps during the transition period from Jerrett to Gallagher.

BETHLEHEM, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that after almost 21 years of service to the Company, Jack E. Jerrett is retiring as the Company’s Senior Vice President, General Counsel, Chief Compliance Officer and Secretary, effective as of December 31, 2021. Agnieszka M. Gallagher, who most recently served as the Chief Ethics and Compliance Officer at Alnylam Pharmaceuticals has been hired by the Company to fill Jack’s roles as the new General Counsel, Chief Compliance Officer and Secretary.

“Jack has been a stalwart and extremely dedicated member of OraSure’s executive leadership team for over two decades and his countless contributions to the Company’s growth and development deserve our significant gratitude and appreciation,” said Stephen S. Tang, Ph.D., President and Chief Executive Officer of OraSure Technologies. “While Jack’s leadership, experience, and friendship will be sorely missed by the organization, we are fortunate to have an outstanding replacement with Aggie joining the Company and we are exceptionally pleased to add her to the executive leadership team.”

Ms. Gallagher, age 48, brings to OraSure a strong background with over two decades of legal and compliance executive leadership experience. Most recently, Ms. Gallagher served as the Chief Ethics and Compliance Officer for Alnylam Pharmaceuticals, a large cap biopharmaceutical company focused on RNAi therapeutics. Prior to joining Alnylam, Ms. Gallagher was the General Counsel, Secretary, and Chief Compliance Officer of ViiV Healthcare, overseeing a multi-billion dollar annual business. Before ViiV Healthcare, Ms. Gallagher served on GSK Vaccines executive team as Vice President, Ethics and Compliance Officer, and prior to that she led GSK Vaccines’ legal and antitrust work following its $5 billion acquisition of Novartis Vaccines. Before joining GSK, Ms. Gallagher served in leadership roles in the legal and compliance functions at Sandoz (a Novartis Company), Medtronic Inc., and Pfizer Inc.  

Mrs. Gallagher holds a Juris Doctorate from Rutgers Law School and a Bachelor of Arts Degree in Spanish from Rutgers College.

About OraSure Technologies
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.

Investor Contact:	Media Contact:
Scott Gleason	Amy Koch
Interim CFO & SVP Investor Relations & Corp. Communications	Sr. Mgr. Corporate Communications
484-425-0588	484-523-1815
sgleason@orasure.com	media@orasure.com

FAQ

Who is replacing Jack E. Jerrett at OraSure Technologies?

Agnieszka M. Gallagher will replace Jack E. Jerrett as Senior VP, General Counsel, Chief Compliance Officer, and Secretary effective December 31, 2021.

What experience does Agnieszka M. Gallagher bring to OraSure Technologies?

Gallagher has over 20 years of legal and compliance experience, previously serving as Chief Ethics and Compliance Officer at Alnylam Pharmaceuticals.

Why is Jack E. Jerrett retiring from OraSure Technologies?

Jack E. Jerrett is retiring after nearly 21 years of service, although specific reasons for his retirement were not disclosed.

What impact might the management change have on OraSure Technologies?

The management change may lead to strategic shifts in leadership, but potential experience gaps could create continuity challenges.